ablol-5, 0,5%, collyre /eye drop, fl/10 ml
abacus parental drugs limited - timolol - collyre /eye drop - 0,5%
abnal, 0;9%, goutte nasale, fl/10 ml
abacus parental drugs limited - chlorure de sodium - goutte nasale - 0;9%
cifin, 0.2%, solution injectable, fl/100 ml
abacus parental drugs limited - ciprofloxacine - solution injectable - 0.2%
ciprocin, 0.3%, solution pour lavage ophtalmique, fl/10 ml
abacus parental drugs limited - ciprofloxacine - solution pour lavage ophtalmique - 0.3%
d5, 5%, solution injectable pour perfusion, fl/500ml
abacus parental drugs limited - sérum glucosé - solution injectable pour perfusion - 5%
d50, 50%, solution injectable pour perfusion, 500 ml
abacus parental drugs limited - le sÉrum glucose - solution injectable pour perfusion - 50%
rl, , solution injectable pour perfusion, fl/500 ml
abacus parental drugs limited - ringer lactate - solution injectable pour perfusion
x beta n, 0.1%/0.5%, goutte nasale, fl/10 ml
abacus parental drugs limited - betamethasone/ neomycine - goutte nasale - 0.1%/0.5%
x sone n, 0.35%/0.1%, goutte nasale, fl./10 ml
abacus parental drugs limited - dexamethason+neomycine - goutte nasale - 0.35%/0.1%
thiotepa riemser
esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - agents antinéoplasiques - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.